Loading clinical trials...
Loading clinical trials...
A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia
Conditions
Interventions
OFC Infusion
FC infusion
Locations
135
United States
Novartis Investigative Site
Boca Raton, Florida, United States
Novartis Investigative Site
Chicago, Illinois, United States
Novartis Investigative Site
Clinton, Maryland, United States
Novartis Investigative Site
Kansas City, Missouri, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Memphis, Tennessee, United States
Start Date
March 12, 2009
Primary Completion Date
December 17, 2014
Completion Date
October 25, 2017
Last Updated
June 18, 2020
NCT00742144
NCT01077622
NCT01563055
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions